NCT03707899

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Co-administration of Telmisartan/Amlodipine and Rosuvastatin in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Jeil Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers.

Conditions

• Hypertension With Dyslipidemia

Interventions

Type	Name	Description
DRUG	JLP-1401	Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
DRUG	Telmisartan/Amlodipine, Rosuvastatin	Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)

Timeline

• Start date: 2018-12-13
• Primary completion: 2019-02-18
• Completion: 2019-05-22
• First posted: 2018-10-16
• Last updated: 2019-08-29

Locations

1 site across 1 country: South Korea